Author | Ophthalmology Times Staff Reports

Articles

Bausch Health: Spin-off of eye health business

August 06, 2020

Article

This action will result in 2 separate companies

DME therapy with plasma kallikrein inhibitor showing promise

May 03, 2016

Article

Results from a phase I study of KVD001 (KalVista Pharmaceuticals) for the treatment of central involved diabetic macular edema (CIDME) show that this plasma kallikrein inhibitor was well-tolerated, not associated with any ophthalmic or systemic safety signals, and led to fairly long-lasting improvements in visual acuity (VA) and central retinal thickness (CRT) after a single intravitreous injection.